Abstract

BackgroundIn this study, we investigated whether the infusion of bone marrow-derived mesenchymal stem cells (MSCs), combined with transient immunosuppressant treatment, could suppress allograft rejection and modulate T-cell regulation in a swine orthotopic hemi-facial composite tissue allotransplantation (CTA) model.Methodology/Principal FindingsOutbred miniature swine underwent hemi-facial allotransplantation (day 0). Group-I (n = 5) consisted of untreated control animals. Group-II (n = 3) animals received MSCs alone (given on days −1, +1, +3, +7, +14, and +21). Group-III (n = 3) animals received CsA (days 0 to +28). Group-IV (n = 5) animals received CsA (days 0 to +28) and MSCs (days −1, +1, +3, +7, +14, and +21). The transplanted face tissue was observed daily for signs of rejection. Biopsies of donor tissues and recipient blood sample were obtained at specified predetermined times (per 2 weeks post-transplant) or at the time of clinically evident rejection. Our results indicated that the MSC-CsA group had significantly prolonged allograft survival compared to the other groups (P<0.001). Histological examination of the MSC-CsA group displayed the lowest degree of rejection in alloskin and lymphoid gland tissues. TNF-α expression in circulating blood revealed significant suppression in the MSC and MSC-CsA treatment groups, as compared to that in controls. IHC staining showed CD45 and IL-6 expression were significantly decreased in MSC-CsA treatment groups compared to controls. The number of CD4+/CD25+ regulatory T-cells and IL-10 expressions in the circulating blood significantly increased in the MSC-CsA group compared to the other groups. IHC staining of alloskin tissue biopsies revealed a significant increase in the numbers of foxp3+T-cells and TGF-β1 positive cells in the MSC-CsA group compared to the other groups.ConclusionsThese results demonstrate that MSCs significantly prolong hemifacial CTA survival. Our data indicate the MSCs did not only suppress inflammation and acute rejection of CTA, but also modulate T-cell regulation and related cytokines expression.

Highlights

  • Mesenchymal stem cells (MSCs) from the bone marrow are multi-potential non-hematopoietic progenitor cells in the adult marrow capable of differentiating into various mesenchymal cell types

  • These results demonstrate that mesenchymal stem cells (MSCs) significantly prolong hemifacial composite tissue allotransplantation (CTA) survival

  • We clearly showed that donor bone marrow-derived MSC therapy, in addition to bone marrow transplantation (BMT), after total body irradiation and short-term cyclosporine A (CsA) treatment significantly improved allotransplant survival without signs of graftversus-host disease (GVHD) in a swine heterotopic hind-limb composite tissue allotransplantation (CTA) model [5]

Read more

Summary

Introduction

Mesenchymal stem cells (MSCs) from the bone marrow are multi-potential non-hematopoietic progenitor cells in the adult marrow capable of differentiating into various mesenchymal cell types. Studies have indicated that donor MSCs are potent inhibitors of T-cell proliferation in mixed lymphocyte cultures, preventing graftversus-host disease (GVHD) caused by bone marrow transplantation (BMT) and prolonging skin allograft survival in rodent models [4]. We clearly showed that donor bone marrow-derived MSC therapy, in addition to BMT, after total body irradiation and short-term cyclosporine A (CsA) treatment significantly improved allotransplant survival without signs of GVHD in a swine heterotopic hind-limb composite tissue allotransplantation (CTA) model [5]. We investigated whether the infusion of bone marrow-derived mesenchymal stem cells (MSCs), combined with transient immunosuppressant treatment, could suppress allograft rejection and modulate T-cell regulation in a swine orthotopic hemi-facial composite tissue allotransplantation (CTA) model

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call